Procurement Summary
Country: USA
Summary: Pluvicto and Lutathera | VA GLA
Deadline: 15 Aug 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 123991909
Document Ref. No.: 36C26225Q1321
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Description
NOTICE OF INTENT TO SOLE SOURCE
This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government-s intent to execute a Sole Source Delivery Order under FAR Part 8, specifically FAR Part 8.405-6(a)(1)(B), Only One Available Source. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1, 300 Employees.
The intended contractor is Novartis Pharmaceuticals Corporation located at 59 Route 10, East Handover, NJ 07936. Place of Performance is the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA 90073. VA Greater Los Angeles Nuclear Medicine Service intends to purchase PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML and LUTATHERA LUTETIUM LU 177 DOTATATE in quantities listed below:
NDC#
Contract
Description
Qty
UOM
69488-0010-61
36F79720D0180
PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML
105
EA
69488-0003-01
36F79720D0180
LUTATHERA LUTETIUM LU 177 DOTATATE
10
EA
VA Greater Los Angele Healthcare System Nuclear Medicine Service requires Pluvicto to treat advance prostate cancer and Lutathera to treat neuroendocrine tumor therapy. Radiopharmaceuticals requested were awarded to Novartis Pharmaceuticals Corporations on 7/30/2020 under contract 36F79720D0180.
This notice of intent is neither a formal sol...
Active Contract Opportunity
Notice ID : 36C26225Q1321
Related Notice
Department/Ind. Agency : VETERANS AFFAIRS, DEPARTMENT OF
Sub-tier : VETERANS AFFAIRS, DEPARTMENT OF
Office: 262-NETWORK CONTRACT OFFICE 22 (36C262)
General Information
Contract Opportunity Type: Special Notice (Original)
Original Published Date: Aug 05, 2025 02:04 pm PDT
Original Response Date: Aug 15, 2025 10:00 am PDT
Inactive Policy: Manual
Original Inactive Date: Sep 05, 2025
Initiative: None
Classification
Original Set Aside: No Set aside used
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: Los Angeles, CA 90073 USA
Documents
Tender Notice
S02-36C26225Q1321.docx